Development and clinical use of prasugrel and ticagrelor

• Published in: Current pharmaceutical design Vol. 18; no. 33; p. 5240
• Main Authors: Ahmad, Shiraz, Storey, Robert F
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 2012
• Subjects: Acute Coronary Syndrome - blood; Acute Coronary Syndrome - drug therapy; Adenosine - adverse effects; Adenosine - analogs & derivatives; Adenosine - chemistry; Adenosine - therapeutic use; Animals; Aspirin - therapeutic use; Blood Platelets - drug effects; Blood Platelets - metabolism; Clopidogrel; Drug Design; Hemorrhage - chemically induced; Hemostasis - drug effects; Humans; Patient Selection; Piperazines - adverse effects; Piperazines - chemistry; Piperazines - therapeutic use; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - chemistry; Platelet Aggregation Inhibitors - therapeutic use; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists - adverse effects; Purinergic P2Y Receptor Antagonists - chemistry; Purinergic P2Y Receptor Antagonists - therapeutic use; Receptors, Purinergic P2Y12 - blood; Receptors, Purinergic P2Y12 - drug effects; Risk Factors; Thiophenes - adverse effects; Thiophenes - chemistry; Thiophenes - therapeutic use; Ticagrelor; Ticlopidine - analogs & derivatives; Ticlopidine - therapeutic use; Treatment Outcome
• ISSN: 1873-4286
• DOI: 10.2174/138161212803251989

Anti-platelet agents have left an indelible impression in the management of a wide range of pathologies. From the earliest therapeutic agents such as aspirin, to the cutting edge agents still undergoing development, they have the capability to powerfully manipulate platelet biology, a central player in thrombosis. The use of these agents is still subject to a number of important limitations that two newer agents, prasugrel and ticagrelor, aim to address. Both have recently received licensing for use in acute coronary syndromes and promise to improve outcomes for patients. Here, we examine the rationale for the development and clinical integration of antiplatelet agents focusing upon prasugrel and ticagrelor.